Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. - Test2 - elhamkhani - TriplyDB

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

http://www.wikidata.org/entity/Q34056639

about

Concise review: Leukemia stem cells in personalized medicine Jaundice and hepatorenal syndrome associated with cytosine arabinoside Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.Intensive consolidation chemotherapy for acute lymphoblastic leukaemia (UKALL X pilot study).Cell-based evaluation of changes in coagulation activity induced by antineoplastic drugs for the treatment of acute myeloid leukemia Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.Minimal residual disease in acute myeloid leukaemia A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias Anthracycline dose intensification in acute myeloid leukemia.Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML.Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current Literature.Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells.Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.Development of therapeutic agents for older patients with acute myelogenous leukemia.Anthracycline dose intensification in young adults with acute myeloid leukemia.Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.A polymorphism in the 3'-untranslated region of the NPM1 gene causes illegitimate regulation by microRNA-337-5p and correlates with adverse outcome in acute myeloid leukemia.Acute myeloid leukaemia: optimal management and recent developments.Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours.RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.Acute myeloid leukemia: focus on novel therapeutic strategies.Remission induction in acute myeloid leukemia.Frontline treatment of acute myeloid leukemia in adults.Improved Survival With Integration of Chinese Herbal Medicine Therapy in Patients With Acute Myeloid Leukemia: A Nationwide Population-Based Cohort Study.Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.Update on optimal management of acute myeloid leukemia Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML

P2860

Q26995268-3F895577-770F-486C-B6D1-7ECB487E5C0D Q28334491-F9A6DE9F-0EB7-4F09-AAAB-7E9F2786C400 Q30620658-8227B013-0245-4445-9DC3-104600294BD5 Q33437992-6E56BAD0-574E-48CF-A1EB-D1541F8DB1D0 Q33452218-DB701AEC-8D6D-4FF4-A8D4-6367CB5F577C Q33563067-0A38B2E1-5BD4-4B03-85BC-A37C871CDE52 Q33949752-87B8BC18-999D-4149-BF5E-D3C98224AF3F Q34179265-05AA6887-7B0A-4582-A647-2F6F60949260 Q34238046-B25FFF12-CD2F-459E-AA9F-E5A66ED24F04 Q34612121-7C2F6020-1A6E-43BD-A374-BC1D73AB601C Q35018112-C28C2275-3CD9-44EC-8BDE-4B23161A0EF6 Q35546219-04F2103B-4B87-473F-8251-ED9C46CBC1C7 Q35671452-D24C424E-B66C-4E63-892B-B91932F08F00 Q35789387-02EE25E1-3044-4B4B-8152-E965A14DCAB6 Q35803001-3F48AA6B-BE73-4785-8C76-51F3DAF4006A Q35984641-5B494AF5-71F5-4A69-A499-FD94F9527C04 Q36015334-0820BEB5-F7F0-47AB-83B3-EDB5BEEA1251 Q36256357-0CD88659-74D6-4764-8249-DC3485A9696F Q36344469-5C0F0DB2-2702-4ACB-8BD7-6C59774F2C27 Q36358267-2D15DD67-DFEB-4C98-B786-0E279A0C153A Q36366636-B49A83F0-3BE7-4AC2-A5BD-E31ACD5EB468 Q36424315-080EA7C3-3E14-4E26-BB93-F34492327B2C Q36612663-FEDD2BDF-9544-4522-BE63-CED9CD7DE608 Q36709001-1D4E548E-DA4F-4AC1-8717-D2271ABF7B1B Q36892590-E29E851C-BC23-47B4-8036-EE0773E4C1D6 Q36914091-92906DAD-194C-43F4-87D8-4C9B100B3F72 Q37301691-01A3E88F-DF94-4B06-893B-9AC628985CEE Q37352626-55DB9BED-5CB3-45C0-A32B-ECE8C0BA8E4F Q37704367-C350DC6A-E9AD-46BA-A743-147F5C1BB2F3 Q38015336-E3C0D0C7-D53E-4CF8-9A66-50C8B35B7948 Q38026006-6ED0D5BC-F310-4922-B893-080B394F0856 Q38767583-C28485B1-387C-4358-9084-8C6179F0126A Q39483755-61589359-22BF-48D9-970E-38B95C894DEE Q41674738-947A6B56-842C-4426-9943-045289D618DE Q41894404-07519F45-728C-4AB3-8BE8-E2E921B9D5E1 Q49840237-1E3EEF55-617F-4B2C-BCA0-B4AE72ADABF3 Q55472969-7D289C79-3E00-4BAB-818F-C8B3358DF7E3 Q58562912-70379DBD-CFAF-4EEF-B1B0-E881515B5A99

P2860

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

http://www.wikidata.org/entity/Q34056639

description

1981 nî lūn-bûn

@nan

1981 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1981 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1981年の論文

@ja

1981年学术文章

@wuu

1981年学术文章

@zh-cn

1981年学术文章

@zh-hans

1981年学术文章

@zh-my

1981年学术文章

@zh-sg

1981年學術文章

@yue

name

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

@ast

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

@en

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

@nl

type

label

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

@ast

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

@en

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

@nl

prefLabel

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

@ast

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

@en

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

@nl

P1433

Q34056639-293BA792-BD30-4D17-AAA1-AE5181EA1C2D

P1476

Q34056639-B61CC2C6-F2B9-423C-92DF-E4FAA14DF12B

P2093

Q34056639-0D5E8732-E92F-406D-86C3-B4E3C3F99B1D

Q34056639-0E0039FD-5443-4714-9361-447D4C186D8D

Q34056639-1A8C9CB3-26F0-4E47-9A8F-29C8E4B7004B

Q34056639-24E8EBDB-628B-4A74-8554-F10A9A9E060F

Q34056639-27FBEBE5-4CBA-4F7D-B183-FE2AD0F5BCB6

Q34056639-54A4AE96-46A5-4BAD-B07B-50244B400BD8

Q34056639-63B1AEE1-D642-46AB-B7A5-D6A35938C072

Q34056639-648E8106-B971-4348-89EA-BF9863B77FB2

Q34056639-6A463027-0145-41CC-AB57-D462CE31030E

Q34056639-6CDF1A5B-9A99-4E8B-986F-8D548175D37B

P304

Q34056639-452D0048-BDB2-4787-A0FB-1EA8BA9DEDC4

P31

Q34056639-B6352F47-7606-4B4A-B77C-8BA0EA171027

P407

Q34056639-35E2F4B7-978D-4032-B1ED-40254A1AEF42

P433

Q34056639-DCCA8C9E-261D-4D54-8F63-D5E72B5A23D8

P478

Q34056639-CB4A3300-BAAF-4DC7-B6D9-0DDF3AACF20F

P50

Q34056639-3EF8D319-521B-4E6E-8080-4F3DB29B0D10

P577

Q34056639-0AD1FFF2-7AFD-48C5-8A0B-D731267193D2

P698

Q34056639-DF3DE071-EA49-4F82-9ED2-89844F45F662

P921

Q34056639-0CFE3365-B6A2-45EF-AC76-7BF45F04BAFE

P1433

P1476

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B

@en

P2093

Bank A

http://www.w3.org/2001/XMLSchema#string

Blom J

http://www.w3.org/2001/XMLSchema#string

Bloomfield CD

http://www.w3.org/2001/XMLSchema#string

Brunner K

http://www.w3.org/2001/XMLSchema#string

Carey RW

http://www.w3.org/2001/XMLSchema#string

Cooper MR

http://www.w3.org/2001/XMLSchema#string

Ellison RR

http://www.w3.org/2001/XMLSchema#string

Falkson G

http://www.w3.org/2001/XMLSchema#string

Glidewell OJ

http://www.w3.org/2001/XMLSchema#string

Gottlieb A

http://www.w3.org/2001/XMLSchema#string

P304

1203-1212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Clara D. Bloomfield

P577

1981-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

6946847

http://www.w3.org/2001/XMLSchema#string

P921